ϟ
 
DOI: 10.4155/tde.12.144
¤ OpenAccess: Green
This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.

Nanomedicine for uterine leiomyoma therapy

Hazem Ali,Gökhan Kılıç,Kathleen L. Vincent,Massoud Motamedi,Erik Rytting

Leiomyoma
Nanoparticle
Nanomedicine
2013
Background: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. Methods/Results: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and x-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 µM. Conclusion: This novel approach represents a potential fertility-preserving alternative to hysterectomy.
Loading...
    Cite this:
Generate Citation
Powered by Citationsy*
    Nanomedicine for uterine leiomyoma therapy” is a paper by Hazem Ali Gökhan Kılıç Kathleen L. Vincent Massoud Motamedi Erik Rytting published in 2013. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.